<bill session="115" type="h" number="878" updated="2017-10-13T07:15:59Z">
  <state datetime="2017-02-06">REFERRED</state>
  <status>
    <introduced datetime="2017-02-06"/>
  </status>
  <introduced datetime="2017-02-06"/>
  <titles>
    <title type="short" as="introduced">Right to Try Act of 2017</title>
    <title type="short" as="introduced">Right to Try Act of 2017</title>
    <title type="official" as="introduced">To authorize the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law, and for other purposes.</title>
    <title type="display">Right to Try Act of 2017</title>
  </titles>
  <sponsor bioguide_id="B001302"/>
  <cosponsors>
    <cosponsor bioguide_id="A000374" joined="2017-02-16"/>
    <cosponsor bioguide_id="A000375" joined="2017-03-07"/>
    <cosponsor bioguide_id="B001298" joined="2017-02-14"/>
    <cosponsor bioguide_id="B001299" joined="2017-02-06"/>
    <cosponsor bioguide_id="B001282" joined="2017-02-06"/>
    <cosponsor bioguide_id="B001290" joined="2017-02-06"/>
    <cosponsor bioguide_id="B001283" joined="2017-02-06"/>
    <cosponsor bioguide_id="C001072" joined="2017-02-06"/>
    <cosponsor bioguide_id="C001105" joined="2017-08-08"/>
    <cosponsor bioguide_id="C001110" joined="2017-03-13"/>
    <cosponsor bioguide_id="C001096" joined="2017-02-06"/>
    <cosponsor bioguide_id="D000615" joined="2017-02-06"/>
    <cosponsor bioguide_id="F000464" joined="2017-05-16"/>
    <cosponsor bioguide_id="F000466" joined="2017-02-06"/>
    <cosponsor bioguide_id="F000448" joined="2017-02-06"/>
    <cosponsor bioguide_id="G000578" joined="2017-02-14"/>
    <cosponsor bioguide_id="G000552" joined="2017-02-06"/>
    <cosponsor bioguide_id="G000565" joined="2017-10-12"/>
    <cosponsor bioguide_id="G000560" joined="2017-02-21"/>
    <cosponsor bioguide_id="G000568" joined="2017-02-14"/>
    <cosponsor bioguide_id="G000576" joined="2017-02-06"/>
    <cosponsor bioguide_id="H001053" joined="2017-07-12"/>
    <cosponsor bioguide_id="H001036" joined="2017-02-14"/>
    <cosponsor bioguide_id="I000056" joined="2017-02-06"/>
    <cosponsor bioguide_id="L000564" joined="2017-02-06"/>
    <cosponsor bioguide_id="L000567" joined="2017-02-06"/>
    <cosponsor bioguide_id="L000587" joined="2017-02-06"/>
    <cosponsor bioguide_id="M001179" joined="2017-02-06"/>
    <cosponsor bioguide_id="M001197" joined="2017-02-06"/>
    <cosponsor bioguide_id="M001189" joined="2017-02-06"/>
    <cosponsor bioguide_id="O000168" joined="2017-02-06"/>
    <cosponsor bioguide_id="P000606" joined="2017-02-06"/>
    <cosponsor bioguide_id="P000592" joined="2017-06-13"/>
    <cosponsor bioguide_id="P000598" joined="2017-06-06"/>
    <cosponsor bioguide_id="P000599" joined="2017-02-16"/>
    <cosponsor bioguide_id="R000409" joined="2017-02-06"/>
    <cosponsor bioguide_id="R000592" joined="2017-02-06"/>
    <cosponsor bioguide_id="S001183" joined="2017-02-06"/>
    <cosponsor bioguide_id="S000244" joined="2017-02-06"/>
    <cosponsor bioguide_id="S001191" joined="2017-02-16"/>
    <cosponsor bioguide_id="S001199" joined="2017-02-06"/>
    <cosponsor bioguide_id="S001192" joined="2017-02-06"/>
    <cosponsor bioguide_id="T000470" joined="2017-02-21"/>
    <cosponsor bioguide_id="Y000065" joined="2017-02-06"/>
  </cosponsors>
  <actions>
    <action datetime="2017-02-06">
      <text>Introduced in House</text>
    </action>
    <action datetime="2017-02-06" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2017-02-06">
      <text>Referred to House Energy and Commerce</text>
    </action>
    <action datetime="2017-02-06">
      <text>Referred to House Judiciary</text>
    </action>
    <action datetime="2017-02-10">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2017-03-02">
      <text>Referred to the Subcommittee on the Constitution and Civil Justice.</text>
    </action>
    <action datetime="2017-03-02">
      <text>Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSJU" name="House Judiciary" activity="Referral"/>
    <committee subcommittee="Crime, Terrorism, Homeland Security, and Investigations" code="HSJU08" name="House Judiciary" activity="Referral"/>
    <committee subcommittee="Constitution and Civil Justice" code="HSJU10" name="House Judiciary" activity="Referral"/>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
    <committee subcommittee="Health" code="HSIF14" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="s" session="115" relation="unknown" number="204"/>
    <bill type="h" session="115" relation="unknown" number="2368"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Civil actions and liability"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Licensing and registrations"/>
    <term name="Long-term, rehabilitative, and terminal care"/>
    <term name="Prescription drugs"/>
    <term name="Product safety and quality"/>
  </subjects>
  <amendments/>
  <summary date="2017-02-06T05:00:00Z" status="Introduced in House">Right to Try Act of 2017

This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are: (1) intended to treat a patient who has been diagnosed with a terminal illness, and (2) authorized by state law. The federal government must allow unrestricted possession and use of such treatments by patients certified by a physician as having exhausted all other treatment options.

A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment.

The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment.

The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration; and (3) not be approved, licensed, or cleared for sale under the Federal Food, Drug, or Cosmetic Act or the Public Health Service Act.</summary>
  <committee-reports/>
</bill>
